Progressive Cholestasis and Associated Sclerosing Cholangitis Are Frequent Complications of COVID-19 in Patients with Chronic Liver Disease
Overview
Authors
Affiliations
Background And Aims: Cholestasis is associated with disease severity and worse outcome in COVID-19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described.
Approach And Results: Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Patients were stratified as having (i) no chronic liver disease (CLD), (ii) non-advanced CLD (non-ACLD), or (iii) advanced CLD (ACLD). Patients with CLD and non-COVID-19 pneumonia were matched to patients with CLD and COVID-19 as a control cohort. Liver chemistries before (Pre) and at first, second, and third blood withdrawal after SARS-CoV-2 infection (T1-T3) and at last available time point (last) were recorded. A total of 496 patients were included. In total, 13.1% (n = 65) had CLD (non-ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID-19-related liver injury was more common among patients with CLD (24.6% vs. 10.6%; p = 0.001). After SARS-CoV-2 infection, patients with CLD exhibited progressive cholestasis with persistently increasing levels of alkaline phosphatase (Pre: 91.0 vs. T1: 121.0 vs. last: 175.0 U/L; p < 0.001) and gamma-glutamyl transferase (Pre: 95.0 vs. T1: 135.0 vs. last: 202.0 U/L; p = 0.001). A total of 23.1% of patients with CLD (n = 15/65) developed cholestatic liver failure (cholestasis plus bilirubin ≥6 mg/dl) during COVID-19, and 15.4% of patients (n = 10/65) developed SSC. SSC was significantly more frequent among patients with CLD and COVID-19 than in patients with CLD and non-COVID-19 pneumonia (p = 0.040). COVID-19-associated SSC occurred predominantly in patients with NAFLD/NASH and metabolic risk factors. A total of 26.3% (n = 5/19) of patients with ACLD experienced hepatic decompensation after SARS-CoV-2 infection.
Conclusions: About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.
A cross-sectional study of laboratory parameters 5-6 months after the first COVID-19 infection.
Zore T, Lojk J, Rebersek K, Alic E, Primozic U, Stiglic A Heliyon. 2025; 11(4):e42535.
PMID: 40034304 PMC: 11872526. DOI: 10.1016/j.heliyon.2025.e42535.
Gut microbiota in gastrointestinal diseases: Insights and therapeutic strategies.
Jiang L, Fan J World J Gastroenterol. 2024; 30(39):4329-4332.
PMID: 39492827 PMC: 11525853. DOI: 10.3748/wjg.v30.i39.4329.
Schneeweiss-Gleixner M, Krenn K, Petter M, Haselwanter P, Kraft F, Adam L Sci Rep. 2024; 14(1):23377.
PMID: 39379494 PMC: 11461911. DOI: 10.1038/s41598-024-73948-x.
Fang D, Wu L, Gan B, Guo C, Chen Z, Zhou S BMC Gastroenterol. 2024; 24(1):317.
PMID: 39289600 PMC: 11409749. DOI: 10.1186/s12876-024-03412-7.
Jacobs A, Morley S, Samuel K, Morgan K, Boswell L, Kendall T World J Gastroenterol. 2024; 30(31):3705-3716.
PMID: 39192998 PMC: 11346159. DOI: 10.3748/wjg.v30.i31.3705.